

Michael S Vincent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10485346/publications.pdf>

Version: 2024-02-01

18
papers

1,255
citations

623734

14
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

1671
citing authors

#	ARTICLE	IF	CITATIONS
1	Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1318-1328.	2.9	30
2	Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 333-342.	1.2	23
3	Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study. <i>Clinical and Translational Science</i> , 2021, 14, 671-682.	3.1	18
4	Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. <i>Lancet Rheumatology</i> , The, 2021, 3, e204-e213.	3.9	15
5	A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 379-387.	1.2	92
6	Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2019, 155, 1371.	4.1	174
7	QuickRNASeq: Guide for Pipeline Implementation and for Interactive Results Visualization. <i>Methods in Molecular Biology</i> , 2018, 1751, 57-70.	0.9	5
8	Discovering in vivo cytokine-eQTL interactions from a lupus clinical trial. <i>Genome Biology</i> , 2018, 19, 168.	8.8	36
9	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 534-542.	0.9	111
10	Serum lipids regulate dendritic cell CD1 expression and function. <i>Immunology</i> , 2008, 125, 289-301.	4.4	71
11	CD1a-, b-, and c-Restricted TCRs Recognize Both Self and Foreign Antigens. <i>Journal of Immunology</i> , 2005, 175, 6344-6351.	0.8	45
12	Understanding the function of CD1-restricted T cells. <i>Nature Immunology</i> , 2003, 4, 517-523.	14.5	113
13	CD1-mediated $\hat{I}^3\hat{I}^1$ T Cell Maturation of Dendritic Cells. <i>Journal of Experimental Medicine</i> , 2002, 196, 1575-1584.	8.5	194
14	CD1-dependent dendritic cell instruction. <i>Nature Immunology</i> , 2002, 3, 1163-1168.	14.5	201
15	Apoptosis of Fas ^{high} CD4 ⁺ Synovial T Cells by Borrelia-reactive Fas-ligand ^{high} $\hat{I}^3\hat{I}^1$ T Cells in Lyme Arthritis. <i>Journal of Experimental Medicine</i> , 1996, 184, 2109-2118.	8.5	104
16	Partial purification of dihydrotetrabenazine binding activity from bovine adrenal. <i>Biochemical Pharmacology</i> , 1990, 39, 1823-1825.	4.4	2
17	Interaction of dihydrotetrabenazine binding activity with immobilized lectins. <i>European Journal of Pharmacology</i> , 1989, 172, 317-319.	2.6	2
18	Distribution of [³ H]Dihydrotetrabenazine Binding in Bovine Striatal Subsynaptic Fractions: Enrichment of Higher Affinity Binding in a Synaptic Vesicle Fraction. <i>Journal of Neurochemistry</i> , 1988, 50, 824-830.	3.9	16